NCT01824615View on ClinicalTrials.gov

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Ovarian CancerAdverse Effects
Interventions
DRUG

Sunitinib

37.5mg everyday from D1-D28

Trial Locations (1)

106

Cathay General Hospital, Taipei

All Listed Sponsors
lead

Cathay General Hospital

OTHER

NCT01824615 - Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma | Biotech Hunter | Biotech Hunter